

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

VOLUNTARY ANNOUNCEMENT

ASCLETIS ANNOUNCES IND APPROVAL OF ORAL RDRP INHIBITOR ASC10 FOR COVID-19 BY CHINA NMPA

- *Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA*
- *Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a new and differentiated chemical structure*
- *ASC10 is an oral double prodrug. After administration, both ASC10 and molnupiravir are rapidly and completely converted in vivo into the same active metabolite ASC10-A. Ascletis is actively communicating with regulatory authorities to explore the possibility of further accelerating the clinical development of ASC10*

The board of directors (the “**Board**”) of Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”) announces that the China National Medical Products Administration (“**NMPA**”) has approved the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19. Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. Food and Drug Administration (FDA).

ASC10 is an oral double prodrug which has a new and differentiated chemical structure from the single prodrug molnupiravir. After oral administration, both ASC10 and molnupiravir are rapidly and completely converted *in vivo* into the same active metabolite ASC10-A, also known as β -D-N4-hydroxycytidine (NHC). ASC10 was discovered and developed in-house. Ascletis has filed multiple patent applications for ASC10 and its use globally. ASC10 oral tablet formulation for the clinical study was developed with in-house proprietary technology of Ascletis.

By applying a double prodrug strategy, ASC10's permeability in Caco-2 cells (human colorectal adenocarcinoma cells) and active metabolite exposure in monkeys reached 3.2-fold and 2.1-fold of molnupiravir's, respectively. In the SARS-CoV-2 infected mouse models, ASC10 at 240 mg/kg twice daily led to a 4.0 log reduction in viral titer in lungs, equivalent to molnupiravir at 500 mg/kg twice daily¹. Preclinical studies demonstrated that ASC10-A has potent cellular antiviral activity against Omicron variant ($EC_{50} = 0.3 \mu M$), Delta variant ($EC_{50} = 0.5 \mu M$) and wildtype virus ($EC_{50} = 0.7 \mu M$). It also suggested that there were no drug-drug interactions between ASC10 and other common medicines.

¹ Wahl, et al., Nature. 2021 March; 591(7850): 451 -457.

Ascletis is actively communicating with regulatory authorities to explore the possibility of further accelerating the clinical development of ASC10.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to ultimately commercialize ASC10 successfully.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
August 22, 2022

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.